Search
Olezarsen
go.drugbank.com/drugs/DB18728ApprovedInvestigational[L52033] On December 19, 2024, olezarsen was approved by the FDA for the treatment of familial chylomicronemia syndrome.[L52028] It is also being investigated for the treatment of hyperlipidemia.
Carbamide peroxide
go.drugbank.com/drugs/DB11129ApprovedInvestigationalof this ingredient as an oral wound healing agent [L1976]. … As it is a source of hydrogen peroxide, it can be found in disinfecting and dental bleaching products.
Naltrexone
go.drugbank.com/drugs/DB00704ApprovedInvestigationalVet approvedThe FDA has approved naltrexone for the treatment of alcohol dependence. … It is a narcotic antagonist that is effective orally, longer lasting and more potent than naloxone, and has been proposed for the treatment of heroin addiction.
Lapyrium
go.drugbank.com/drugs/DB09376ApprovedLapyrium is a quaternary ammonium cation used as a surfactant, antistatic agent, and biocide in various cosmetic products [A19426]. It is commonly found formulated as lapyrium chloride.
Sirolimus
go.drugbank.com/drugs/DB00877ApprovedInvestigational[A242412] It was first isolated and identified as an antifungal agent with potent anticandida activity; however, after its potent antitumor and immunosuppressive activities were later discovered, it was … [L39267] Sirolimus was also investigated in other cancers such as skin cancer, Kaposi’s Sarcoma, cutaneous T-cell lymphomas, and tuberous sclerosis.
Benzethonium
go.drugbank.com/drugs/DB11125ApprovedBenzethonium was identified as a novel cancer-specific compound by cell-based small-molecule screen [A32298]. … It is additionally found in cosmetics and toiletries such as mouthwashes and anti-itch ointments.
Sevoflurane
go.drugbank.com/drugs/DB01236ApprovedInvestigationalVet approved[L42340] Sevoflurane was patented in 1972, was approved for clinical use in Japan in 1990, and approved by the FDA in 1996. … Unlike other volatile anesthetics, sevoflurane has a pleasant odor and does not irritate the airway.
Pretomanid
go.drugbank.com/drugs/DB05154ApprovedInvestigationalIt was the first TB drug developed by a nonprofit organization, known as TB Alliance, and was granted FDA approval on August 14, 2019. … Research in recent years has been geared toward the development of novel therapies that target persistent forms of this disease, which have shown resistance to standard therapy regimens.
Rosiglitazone
go.drugbank.com/drugs/DB00412ApprovedInvestigationalRosiglitazone is a selective ligand of PPARγ, and has no PPARα-binding action. … Recent research has suggested that rosiglitazone may also be of benefit to a subset of patients with Alzheimer's disease not expressing the ApoE4 allele.
Anifrolumab
go.drugbank.com/drugs/DB11976ApprovedInvestigationalerythematosus, but so far only anifrolumab has been approved. … [A237054] Anifrolumab has also been investigated for the treatment of Scleroderma.[A237044] Anifrolumab was granted FDA approval on 30 July 2021.[L34929]
Products: SAPHNELO 300MG CONCENTRATE FOR SOLUTION FOR INFUSION